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Summary. Background: Direct oral anticoagulants (DOACs) are increasingly being used in the setting of venous thromboembolic disease (VTE). There is little evidence to guide the peri-procedural interruption of DOACs in this patient population. A number of studies have evaluated the perioperative interruption of DOACs based on half-life of the anticoagulant and the underlying procedural bleeding risk in patient with atrial fibrillation, but it remains unclear whether these findings can be extended to patients with VTE. Objective: Evaluate thrombotic and bleeding outcomes following the perioperative interruption of direct oral anticoagulation in patients with prior VTE. Methods: We conducted a retrospective analysis of consecutive patients on a DOAC for prior VTE requiring temporary interruption of anticoagulation for an invasive procedure. The primary efficacy outcome was the 30-day symptomatic VTE rate, and the primary safety outcome was the 30-day major bleeding rate. Secondary outcomes included overall mortality and the rate of clinically relevant non-major bleeding. Results: A total of 190 patients were included in the analysis. The 30-day VTE rate was 1.05% (95% CI, 0.29-3.8%) and the 30-day major bleeding rate was 0.53% (95% CI, 0.09-2.93%). There were no deaths during the 30-day follow-up period. The rate of clinically
Introduction
The use of direct oral anticoagulants (DOACs) in the setting of venous thromboembolism (VTE) is increasingly common [1] [2] [3] [4] . Patients on DOACs for acute or secondary prevention of VTE frequently undergo invasive procedures, and there is little evidence to guide the perioperative interruption of direct oral anticoagulation in this patient population [5] .
Unlike vitamin K antagonists, the DOACs all have relatively short half-lives, as well as a rapid onset of action, thereby allowing for ease of discontinuation and re-initiation during the perioperative period [5] . These properties obviate the need for bridging anticoagulation (e.g. lowmolecular-weight heparin).
A prospective management cohort study evaluating perioperative interruption of dabigatran without bridging anticoagulation in patients with atrial fibrillation was recently published [6] . The timing and DOAC discontinuation and re-initiation were based on the estimated half-life of the DOAC and the underlying bleeding risk from the procedure (standard vs. high bleeding risk). The study reported a low risk of thrombotic and bleeding events, suggesting that such a management strategy is safe and effective [6] . However, it is unclear if these findings are applicable to VTE patients. VTE patients are usually younger and have fewer co-morbidities than patients with atrial fibrillation. This could affect both their risk of bleeding and their risk of thromboembolic complications. Moreover, patients with prior VTE might be particularly prone to develop postoperative provoked VTE. Thus, the risk-benefit balance and optimal management of DOAC anticoagulation might differ in this population. There are no studies showing that a DOAC perioperative management strategy is safe or efficacious among VTE patients [5] .
Therefore, we sought to assess the rate of recurrent VTE and major bleeding complications following the interruption of direct oral anticoagulation in patients with prior venous thrombotic events.
Materials and methods

Study population
Consecutive patients on a DOAC for previous VTE, requiring interruption of DOACs for a procedure/surgery and assessed at The Ottawa Hospital Thrombosis Unit between January 2013 and October 2015 were included in our study. Patients were included if they were receiving rivaroxaban, apixaban or dabigatran at doses . We included patients undergoing both standard risk procedures (e.g. appendectomy, cholecystectomy and major orthopedic surgery) and procedures with increased risk of bleeding (e.g. major cancer surgery, endoscopic large polyp resection and major vascular surgery), both in the inpatient and outpatient settings. Standard and high bleeding risk procedures were defined as per previously published stratification [6] . Patients were excluded from the study if they were on a DOAC exclusively for atrial fibrillation (i.e. no VTE indication). This study was approved by the Research Ethics Board of the Ottawa Hospital Research Institute.
Perioperative anticoagulation
The timing of DOAC interruption and re-initiation was at the discretion of each treating physician. Usual practice is to hold the DOAC for three and five half-lives prior to standard and high bleeding risk procedures, respectively [6] . DOACs are usually re-started on postoperative day (POD) 2 or 4 following standard and high bleeding risk procedures. The decision to use prophylactic doses of LMWH or a DOAC on POD 1 and 2 following high bleeding risk procedures was also at the discretion of each treating physician.
Study outcomes
The primary outcomes of the study were the 30-day symptomatic VTE complication rate, as well as the 30-day major bleeding rate. Recurrent deep vein thrombosis (DVT) was defined as either the (i) new non-compressibility of any vein segment, from the common femoral vein to the trifurcation of the popliteal vein on compressive ultrasonography, or (ii) new non-compressibility of any vein segment from the subclavian vein to the brachial vein on compressive ultrasonography. Recurrent pulmonary embolism (PE) was defined as either (i) a new segmental or greater mismatch defect on V/Q scan, (ii) a new filling defect on pulmonary angiography or (iii) computed tomography pulmonary angiography demonstrating a new intraluminal filling defect in a vessel equal to or larger than a segmental artery. Major bleeding episodes were defined according to both surgical and non-surgical ISTH major bleeding criteria [7, 8] . Secondary outcomes included the 30-day overall mortality rate and clinically relevant non-major bleeding (CRNMB). CRNMB was defined as any bleeding not meeting major bleeding criteria, and resulting in any of the following: (i) medical intervention, (ii) unscheduled physician contact, (iii) temporary cessation of anticoagulation or (iv) pain or impairment. Secondary outcome measures included postoperative arterial events such as myocardial infarctions (MIs), ischemic cerebrovascular accidents (CVAs) and transient ischemic attacks (TIAs), as well as peripheral ischemia/embolism. Myocardial infarction was confirmed by an elevated troponin and creatine kinase, as well as documented clinical suspicion of non-ST elevation myocardial infarction (NSTEMI) or STEMI and coronary angiography if performed. Ischemic CVA was confirmed via cranial computed tomography (CT) or magnetic resonance imaging (MRI). Peripheral embolism/ischemia was confirmed via an elevated CK and angiography or surgical exploration.
Outcomes were assessed by reviewing appropriate documents via electronic medical records (EMRs) up to 30 days post-procedure.
Statistical analysis
Outcomes were analyzed per patient. Patient and treatment characteristics were analyzed using calculation of mean values and standard deviation. Proportions and 95% confidence intervals (CIs) were calculated for all primary and secondary outcomes using Wilson's method without continuity correction. All statistical calculations were completed using StatsDirect version 2.8.0 (StatsDirect Ltd, Altrincham, UK).
Results
Study population
A total of 190 patients were included in the analysis (Fig. 1) , 62.6% of which were male. The mean patient age was 59.1 years (SD = 14.3) ( Table 1 ). The indication for anticoagulation was prior lower limb DVT in 79 patients (41.6%), prior upper extremity DVT in 21 patients (11.1%) and prior PE in 86 patients (45.3%), with (28) or without (58) DVT. The most recent VTE event was considered unprovoked in a majority (80.5%) of patients. Forty-eight patients (25.3%) had recurrent VTE. There were four patients (2.1%) on chronic anticoagulation for CTEPH (one of which had documented prior PE) and two patients on chronic anticoagulation for prior superior vena cava thrombus. Patients had a recent VTE (within 3 months of procedure) in 13.7% of cases, thereby placing them at higher risk of recurrent events. Amongst the 26 patients with VTE within 3 months of the procedure, three had both a DVT and PE, 13 had a PE without DVT, seven had a DVT and three patients had an upper extremity deep vein thrombosis (UEDVT). There were no patients that underwent a procedure within 1 month of experiencing VTE. A majority of patients (90%) were on rivaroxaban anticoagulation. Eleven patients were on concomitant antiplatelet therapy (Table 1) . A thrombophilia was present in 25 patients (13.2%). At the time of the procedure, 14 patients had active cancer and 12 patients had concurrent atrial fibrillation. Sixteen patients (8.4%) had a moderately reduced creatinine clearance, whereas only one patient (0.5%) had a severely reduced creatinine clearance (Table 1) .
Procedures
Procedures were carried out in an inpatient setting in 23.7% of cases, whereas 76.3% of procedures were on an outpatient basis ( Table 2 ). The types of procedures are depicted in Table 3 . High and standard bleeding risk procedures were completed in 24.2% and 75.8% of cases, respectively. Spinal anesthesia was used for 13 procedures (6.8%) and epidural anesthesia was used for three procedures (1.6%).
Perioperative anticoagulation
The mean time from last dose of DOAC to surgery was 56.9 h (SD 17.4) and 69.9 h (SD 17.8) in standard and high bleeding risk procedures, respectively. Mean time to therapeutic DOAC re-initiation was 47.0 h (SD 31.0) and 80.2 h (SD 59.3) in standard and high bleeding risk procedures, respectively (Table 4) . Seventy-eight (41.0%) patients received prophylactic doses of LMWH (n = 37) or DOAC (n = 41) in the immediate postoperative period (e.g. POD1 to POD3) before re-initiation of therapeutic doses of DOACs. Out of the 11 patients on antiplatelet therapy, only one patient had antiplatelet therapy held.
Study outcomes
Overall, two recurrent VTE events (1.05%; 95% CI, 0.29-3.8%) occurred during the 30-day follow-up period. Both recurrent VTE events were upper extremity DVTs (there were no central catheters present in either of these patients). The first event was a right-sided subclavian thrombus that occurred on postoperative day 12 (POD 12) following a right-sided transaxillary first rib resection for thoracic outlet obstruction. The second recurrent VTE was a right-sided UEDVT that occurred on POD 21 following right subclavian vein angiography and balloon angioplasty for thoracic outlet obstruction. There were no postoperative arterial thromboembolic events. There was one surgical major bleeding episode (0.53%; 95% CI, 0.09-2.93%) during the 30-day follow-up period. The patient underwent major cancer surgery, for resection of a locally advanced rectal cancer, with invasion of the bladder and vaginal canal. Excessive bleeding was reported intra-operatively and attributed by the surgeon to altered surgical planes and architecture secondary to the invasive malignancy and extensive fibrosis. This patient did not have any significant renal impairment.
Secondary outcomes included both overall mortality and CRNMB. There were no deaths during the 30-day follow-up period (0%; 95% CI, 0.00-1.98%). There were six CRNMB events (3.16%; 95% CI, 1.46-6.72%). Three episodes of CRNMB led to unscheduled physician contact, two led to temporary cessation of anticoagulation and one required a medical intervention (postoperative transfusion of 2 units pRBCs, not meeting criteria for surgical major bleeding). Two of the CRNMB events occurred during the immediate postoperative period (POD1 and POD2). One was related to surgical blood loss following a total abdominal hysterectomy while the patient was receiving prophylactic doses of LMWH. The other was postoperative hematuria following a transurethral resection of the prostate. The patient was not receiving any anticoagulation at the time of the CRNMB. The other four events were remote (POD 10-23). These four remote events occurred after resuming therapeutic doses of a DOAC. The major bleeding complication occurred in a patient undergoing a high bleeding risk procedure and none of the patients with any bleeding complications (major and CRNMB) had renal dysfunction.
Discussion
Perioperative interruption of DOACs based on the estimated half-life and the underlying risk of bleeding associated with the procedure appears to be efficacious and safe in patients with prior VTE.
To our knowledge, this study represents the first evaluation of the perioperative interruption of direct oral anticoagulation in patients with prior VTE. This study demonstrates that the perioperative interruption of DOACs surrounding planned non-urgent invasive procedures in patients with prior VTE appears to be relatively efficacious and safe, from the standpoint of both the thrombotic and bleeding risk. Only a few studies have been conducted surrounding the perioperative interruption of DOACs in the setting of atrial fibrillation [6, 9, 10] . A recently published prospective study [6] evaluating the perioperative interruption of dabigatran in patients with atrial fibrillation found comparable thromboembolic and major bleeding rates to those reported in our study. Although our findings are reassuring, prospective studies assessing this management strategy in patients with VTE are desperately needed. The risk of recurrent VTE was low in our study (1.05%; 95% CI, 0.29-3.8%). The two recurrent events reported occurred in locations directly affected by the procedure. These findings are also similar to another retrospective study assessing the efficacy and safety of perioperative interruption of warfarin in patients with prior VTE [11] . The investigators from this study reported a 30-day VTE rate of 0.2% (95% CI, 0.06-0.49%) following the perioperative interruption of warfarin [11] . Similarly, the major bleeding rate in our study (0.53%; 95% CI, 0.09-2.93%) is comparable to the rate (0.8%; 95% CI, 0.46-1.29%) reported by Clark and colleagues in their retrospective analysis for patients on warfarin with prior VTE [11] . Our results also compare favorably with the major bleeding rate found in the BRIDGE trial, with respect to both the no-bridging (1.3%) and bridging (3.2%) groups, although this was in the setting of atrial fibrillation and included a larger proportion of high bleeding risk procedures [12] . When compared with a systematic review of 34 studies looking at patients on warfarin anticoagulation for either atrial fibrillation or VTE, our major bleeding rate is also found to be similar (0.9%; 95% CI, 0.2-1.6) [13] .
Our study has several important limitations. First, this was a retrospective study and we cannot rule out the presence of unmeasured selection of misclassification biases. Second, the number of outcome events is relatively small, leading to wide confidence intervals. Third, documentation of the procedure itself was only available in 121 patients. If a major bleeding event did occur during the procedure, this was likely to be documented in a postoperative clinical note. However, we cannot exclude the possibility that bleeding events were missed in those cases where procedural documentation was absent. Fourth, we only included patients undergoing elective procedures within the study. Therefore, the findings cannot be extrapolated to patients undergoing emergent procedures. Further studies are required to guide clinicians regarding this important patient population. Fifth, the diagnosis of recurrent VTE is controversial. We used a previously validated definition for our primary outcomes measure [14] . However, the use of a different definition might have led to a different rate of recurrent VTE in the postoperative period [15] . Finally, a large majority of included patients were on rivaroxaban (90%). Very few patients were on either apixaban or dabigatran for VTE prevention. Although the pharmacokinetics of the three DOACs evaluated in our study are similar, additional studies that include patients on the other DOACs are needed in order to confirm our findings and ensure generalizability.
The perioperative interruption of DOACs in the setting of VTE, using a strategy that takes into account the halflife of the DOAC and the underlying procedural bleeding risk, appears to be both safe and effective. Larger prospective studies are necessary to confirm our findings.
